Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload
| Status: | Archived |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | March 2010 |
A One-year Open-label Extension to a Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload (THALASSA)
This study will evaluate the safety and efficacy of deferasirox in non-transfusion-dependent
thalassemia patients with iron overload. Patients who complete the core study phase (placebo
or active treatment with deferasirox for 12 months) will be offered to continue their study
with the active treatment (deferasirox) in a 12 months extension phase. During the
extension, the effects of treatment on iron overload in the liver will be evaluated using
magnetic resonance imaging (MRI) assessments.
We found this trial at
3
sites
9300 Valley Children's Pl
Madera, California 93720
Madera, California 93720
(559) 353-3000
Children's Hospital Central California The Children's Hospital Central California is a not-for-profit, state-of-the-art children’s hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials